Posted on 394
Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the appointment of Nikola Trbovic, Ph.D., Executive Director and Partner at Pfizer Ventures, as a member of its Board of Directors.
“Nikola’s expertise in R&D and corporate finance will be an asset to Palleon, and we are very pleased to welcome him to the Board. Nikola will replace Bill Burkoth, who we would like to thank for the valuable support and guidance that he has given to Palleon over the years,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “This is an exciting time of growth for the company as our lead program, an enzymatic sialoglycan degrader for T cell exhaustion in cancer, is expected to enter clinical testing later this year. We look forward to working closely with Nikola as we advance our programs to first
11 Best Quantum Computing Stocks to Buy Now
CBInsights defines quantum computing as the process of information that is represented by special quantum states. By tapping into quantum phenomena like “superposition” and “entanglement,” these machines handle information in a fundamentally different way to “classical” computers like smartphones, laptops, or even today’s most powerful supercomputers. Quantum computing has the power to solve critical computational problems across a wide array of services.
Quantum computing has become viable for the growth of a business and society as a whole. In an study by MarketWatch, The Global Quantum Computing Market was valued at $89 million in 2016 and is projected to reach $949 million by 2025, growing at a CAGR of 30% from 2017 to 2025. In a separate study by McKinsey, there will be an estimated 2,000 to 5,000 quantum computers worldwide by 2030. Automotive will be one of the primary sectors for quantum computing with a high impact
What it does:10x Genomics makes software for researchers to perform single cell and whole genome sequencing. Its software can be used for immunotherapy and cell therapy research in cancer patients or patients with rare genetic disorders. The Silicon Valley-based company was founded by Serge Saxonov, formerly the founding director of research at consumer genetics company 23andMe.
Deal details: SoftBank participated in the company s $125 million Series D funding round in 2018 that valued the company at $1.25 billion. It went public in September 2019 and was valued above $3.6 billion in its debut. SoftBank is no longer invested in 10x Genomics.
Other investors: Venrock, Fidelity International, Foresight Capital Management, and Paladin Capital Group
Seattle biotech startup AltPep raises $23.1M to tackle Alzheimer’s and related diseases
January 14, 2021 at 3:54 pm
Valerie Daggett, founder and CEO of AltPep. (UW Photo)
AltPep, a Seattle-based biotech startup tackling amyloid protein disorders, has raised $23.1 million in a Series A funding round.
The venture spun out the University of Washington in March 2019. Its founder and CEO is Valerie Daggett, a longtime professor in the Department of Bioengineering in the College of Engineering.
AltPep is developing tools and treatments for diseases caused by amyloid proteins that are incorrectly folded and create harmful deposits. These deposits can lead to numerous amyloid diseases including Alzheimer’s, Parkinson’s, type-2 diabetes, some kinds of drug-resistant bacterial infections, and dozens more.
AltPep Raises $23M Jumpstarting Work on Alzheimer s Disease
Search jobs SEATTLE - January 14, 2021 - (Newswire.com)
AltPep Corporation, a privately held biomedical company focused on diagnosing and treating Central Nervous System amyloid disorders, starting with Alzheimer s Disease, today announced it closed a $23.150 million Series A investment round. Matrix Capital Management led the investment, with significant participation by Alexandria Venture Investments. In conjunction with the financing, David Goel, Managing General Partner and Founder of Matrix Capital Management and Joel Marcus, Executive Chairman and Founder of Alexandria Real Estate Equities/Alexandria Venture Investments, have joined the AltPep Board of Directors.
The proceeds of the Series A investment will be used to advance a breakthrough technology developed at the University of Washington laboratory of AltPep Founder and CEO, Valerie Daggett, Ph.D., that targets the misfolded forms of amyloi